Because NAC1 is involved in many melanoma-treatment-related events, we propose that the combination of NAC1 inhibition and the inhibition of the NF-κB pathway may be exploited as a novel approach for the treatment of melanoma. The gene discussed is NFKB1; the disease is melanoma.